The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma
- PMID: 16452176
- DOI: 10.1158/0008-5472.CAN-05-2856
The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma
Abstract
We examined the role of FcgammaR in antibody therapy of metastatic melanoma in wild-type and different FcgammaR knock-out mice. Treatment of B16F10-challenged wild-type mice with TA99 antibody specific for the gp75 tumor antigen resulted in a marked decrease in numbers of lung metastases. Treatment of individual FcgammaR knock-out mice revealed the high-affinity IgG receptor, FcgammaRI (CD64), to represent the central FcgammaR for TA99-induced antitumor effects. The potential of immune-modulating agents to further enhance the protective effect induced by monoclonal antibody (mAb) TA99 was examined in combination treatments consisting of mAb TA99 and a TLR-4 agonist, monophosphoryl lipid A (MPL). MPL did potently boost TA99 antibody-induced effects, and combination therapy was, again, found to be dependent on the presence of FcgammaRI.
Similar articles
-
Cutting edge: FcγRIII (CD16) and FcγRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma.J Immunol. 2012 Dec 15;189(12):5513-7. doi: 10.4049/jimmunol.1201511. Epub 2012 Nov 12. J Immunol. 2012. PMID: 23150715
-
Anti-tumor activity of human IgG1 anti-gp75 TA99 mAb against B16F10 melanoma in human FcgammaRI transgenic mice.Immunol Lett. 2014 Aug;160(2):151-7. doi: 10.1016/j.imlet.2014.02.005. Epub 2014 Mar 5. Immunol Lett. 2014. PMID: 24613852
-
Enhanced suppression of melanoma tumor growth and metastasis by combined therapy with anti-VEGF receptor and anti-TYRP-1/gp75 monoclonal antibodies.Anticancer Res. 2008 Sep-Oct;28(5A):2679-86. Anticancer Res. 2008. PMID: 19035294
-
FcgammaR: The key to optimize therapeutic antibodies?Crit Rev Oncol Hematol. 2007 Apr;62(1):26-33. doi: 10.1016/j.critrevonc.2006.12.003. Epub 2007 Jan 19. Crit Rev Oncol Hematol. 2007. PMID: 17240158 Review.
-
Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions.Cancer Immunol Res. 2015 Jul;3(7):704-13. doi: 10.1158/2326-6066.CIR-15-0120. Cancer Immunol Res. 2015. PMID: 26138698 Review.
Cited by
-
Activating and inhibitory FcgammaRs in autoimmune disorders.Springer Semin Immunopathol. 2006 Dec;28(4):305-19. doi: 10.1007/s00281-006-0052-1. Epub 2006 Oct 1. Springer Semin Immunopathol. 2006. PMID: 17115158 Review.
-
Artificial Anti-Tumor Opsonizing Proteins with Fibronectin Scaffolds Engineered for Specificity to Each of the Murine FcγR Types.J Mol Biol. 2018 Jun 8;430(12):1786-1798. doi: 10.1016/j.jmb.2018.04.021. Epub 2018 Apr 25. J Mol Biol. 2018. PMID: 29704491 Free PMC article.
-
Functional, Biophysical, and Structural Characterization of Human IgG1 and IgG4 Fc Variants with Ablated Immune Functionality.Antibodies (Basel). 2017 Sep 1;6(3):12. doi: 10.3390/antib6030012. Antibodies (Basel). 2017. PMID: 31548527 Free PMC article.
-
Mechanisms of inside-out signaling of the high-affinity IgG receptor FcγRI.Sci Signal. 2018 Jul 24;11(540):eaaq0891. doi: 10.1126/scisignal.aaq0891. Sci Signal. 2018. PMID: 30042128 Free PMC article.
-
Tumoral Interferon Beta Induces an Immune-Stimulatory Phenotype in Tumor-Associated Macrophages in Melanoma Brain Metastases.Cancer Res Commun. 2024 Aug 1;4(8):2189-2202. doi: 10.1158/2767-9764.CRC-24-0024. Cancer Res Commun. 2024. PMID: 39056192 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases